Q3 2025 Management View CEO Kim Kelderman highlighted 6% organic revenue growth amidst a challenging macro environment. Key drivers included strength in core reagents, automated analytical solutions, ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

An international study led by the Institut de Neurociències at the UAB (INc-UAB) has shown that increasing levels of the ...

GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of Natural ...

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

Diagnosed with thalassemia at 7 months, Pratham was cured after 7 years via a stem cell transplant from a stranger. His story ...

The Trump administration initiated a Section 232 investigation into imports of processed critical minerals and their derivate ...

A North Texas senior is fighting for his life after falling from a vehicle while playing a game popular with graduating high ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

FAYETTEVILLE, W.Va. — The Fayette County Board of Education is having discussions on a potential cell phone ban in the ...